Calcibloc® [cap]

MIMS Class : Calcium Antagonists

Contents Nifedipine
Indications All forms of HTN; HTN in pregnancy; coronary insufficiency w/ or w/o
angina; vasospastic angina, to increase heart rate in sinus bradycardia & sick
sinus syndrome.
Dosage Adult 5-10 mg bid-tid.
Administration May be taken with or without food (For rapid effect, bite/ puncture cap
before swallowing. Avoid grapefruit juice.).
Contraindications Acute MI.
Special Close monitoring of BP & titration of initial dose is recommended. Impaired
Precautions liver function.
Adverse Drug Infrequently, flushing, nausea, dizziness, headache, tiredness, sedation; leg
Reactions edema.
View ADR Monitoring Website
Drug Interactions Enhances actions of hypotensive prep & β-blockers.
View more drug interactions with Calcibloc
MIMS Class Calcium Antagonists

Co-Aleva® [tab]
MIMS Class : Antihistamines & Antiallergics
Indications
Treatment of seasonal/perennial allergic rhinitis & chronic urticaria.
Dosage
Adult 1 tab bid.
Overdosage
View Co-Aleva overdosage for action to be taken in the event of an overdose.
Administration
Should be taken with food
Contraindications
Severe liver insufficiency. Lactation.
Caution use in patients w/ known cardiac risk eg long QT syndrome, hypokalemia. Heart
Special
failure, recent MI or HTN, DM, epilepsy, glaucoma, hypothyroidism, hepatic failure,
Precautions
osteoporosis, peptic ulceration, psychoses or severe affective disorders & renal impairment.
Pregnancy.
Headache,
Adverse dry mouth, drowsiness. Less common are pharyngitis, abdominal pain, dyspepsia,
Drug
asthenia, epistaxis, rhinitis, sinusitis, nausea & insomnia.
Reactions

In clinical
Side Effectstrials, the most commonly reported side effects with ebastine were headache, dry
mouth and drowsiness, which were comparable to placebo.

Other less commonly reported adverse events of ebastine include: Pharyngitis, abdominal pain,
dyspepsia, asthenia, epistaxis, rhinitis, sinusitis, nausea and insomnia.
The Interactions
Drug interaction of ebastine in combination with either ketoconazole or
erythromycin (both known to prolong the QTc interval) has been evaluated.
Interaction has been observed with these combinations, resulting in higher
ebastine plasma levels but only in about a 10 millisec increase in QTc greater than
the increase seen with ketoconazole or erythromycin alone.
Pharmacology:
Mechanism of Pharmacodynamics: Pre-Clinical: Ebastine has been shown to
produce
Action a rapid and long-lasting inhibition of histamine-induced effect and to
have a strong affinity towards H1-receptors. Following oral administration neither
ebastine nor its metabolites cross the blood-brain barrier. This characteristic is
consistent with the low sedative profile seen in the results of experiments
studying the effects of ebastine on the CNS.

meloxicam
MIMS Class : Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Dosage Adult: PO/Rectal Ankylosing spondylitis; Rheumatoid arthritis 15
mg once daily. Patients w/ increased risk of adverse effects: Initial:
7.5 mg. Acute exacerbations of osteoarthritis 7.5 mg once daily.
Max: 15 mg once daily.
Click to view Dosage by Indications
Administration May be taken with or without food. (May be taken w/ meals if GI
discomfort occurs.)
Contraindications Hypersensitivity to meloxicam, aspirin or other NSAIDs; severe
hepatic impairment; bleeding disorders; renal failure without dialysis.
Rectal admin in patients with proctitis, haemorrhoids or rectal
bleeding.
Special History of GI disease, asthma, hypertension, CVD or risk factors,
Precautions fluid retention or heart failure. Monitor patients with advanced renal
disease. May impair ability to drive or operate machinery. Elderly.
Pregnancy (avoid in the 3rd trimester) and lactation.
Adverse Drug Dyspepsia, headache, nausea, diarrhoea, upper respiratory tract
Reactions infection, abdominal pain, dizziness, oedema, flatulence, influenza-
like symptoms, back pain, muscle spasms, musculoskeletal pain,
rash, anaemia. GI perforation, ulceration and/or bleeding. In children:
Abdominal pain, vomiting, diarrhoea, headache, pyrexia.
Potentially Fatal: Stevens Johnson syndrome, thrombocytopenia,
interstitial nephritis and idiosyncratic liver abnormality.
Drug Interactions May reduce effects of antihypertensives. Increased clearance with
bile acid sequestrants e.g. colestyramine. Increased risk of renal
failure with diuretics; may reduce natriuretic effects of furosemide
and thiazides. May increase toxicity of methotrexate.
Potentially Fatal: May increase plasma concentrations and toxicity
of lithium. Increased risk of severe GI effects with aspirin, warfarin.

Mechanism of
Action Meloxicam inhibits prostaglandin synthesis by reducing
cyclooxygenase enzyme activity. This results in decreased
production of prostaglandin precursors.
Absorption: Well absorbed from the GI tract (oral).
Distribution: Protein-binding: 99%.
Metabolism: Extensively hepatic via oxidation pathway.
Excretion: Via urine and faeces (as inactive metabolites); 20 hr
(elimination half-life).
MIMS Class Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Ectrin® [cap]
MIMS Class : Cough & Cold Preparations

Indications Treatment of acute bronchitis, chronic bronchitis and its exacerbations.

Respiratory disorders characterized by abnormal bronchial secretions and
impaired mucus transport.
Administration May be taken with or without food
Contraindications Known hypersensitivity to erdosteine. Because of a possible interference of
erdosteine metabolites with the methionine metabolism, erdosteine is
contraindicated in patients suffering from hepatic cirrhosis and deficiency of
the cystathionine-synthetase enzyme.

Suspension: Phenylketonuria, due to the presence of aspartame.

Special Effects on the Ability to Drive or Operate Machinery: No effects have been
Precautions reported.

Use in pregnancy & lactation: The safety of erdosteine during human

pregnancy has not been established and therefore, as with all other new
drugs, its use is not recommended. Ectrin is also not recommended during
lactation.
Side Effects No gastrointestinal nor systemic side effects due to Ectrin have been
observed.
Drug Interactions No harmful interactions have been observed with other medicaments and
Ectrin can therefore be administered together with antibiotics and
bronchodilators (theophylline or β2-mimetics and cough sedatives).
View more drug interactions for Ectrin
Mechanism of Pharmacokinetics: Peak plasma levels are reached after 30-60 min. Ectrin
Action has subsequent complete metabolism in similar metabolites.
Isoprinosine®
MIMS Class : Antivirals

Indications Treatment of various viral infections eg influenza A, rhinovirus, measles,

encephalitis, herpes zoster, herpes simplex labialis, hepatitis A, acute viral
hepatitis B, herpes genitalis; treatment of chickenpox, mumps;
immunorestoration, in those suffering from pre-AIDS/persistent generalized
lymphadenopathy & AIDS related complex.
Administration Should be taken with food
Special Patients w/ gout or renal disturbances. Supervise administration to
Precautions digitalized patients. Pregnancy & lactation.
Adverse Drug Transient elevation of urine &/or serum uric acid levels. Infrequent: Skin
Reactions rashes &/or itching, Gl upset, nausea, fatigue &/or malaise & diarrhea.
Rarely: Headache, vertigo, arthralgia, constipation & polyuria.